Literature DB >> 16434648

Disability progression in multiple sclerosis is slower than previously reported.

Helen Tremlett1, Donald Paty, Virginia Devonshire.   

Abstract

OBJECTIVE: To investigate disease progression and risk factors in a large geographically based population with multiple sclerosis (MS), using two different inception points--clinical onset and date of birth.
METHODS: The authors reviewed a database of subjects with definite MS and symptom onset prior to July 1988. The main outcome was sustained progression to Expanded Disability Status Scale (EDSS) 6 (requires a cane), using the date of birth and date of MS onset as inception points in separate analyses. Risk factors examined were sex, relapsing vs primary progressive course, onset age, and onset symptoms.
RESULTS: The study included 2,837 patients, followed prospectively for 22,723 patient years. The median time to EDSS 6 was 27.9 years, 15 years after onset; only 21% reached EDSS 6, and by age 50, 28% required a cane. Men progressed 38% more quickly than women from onset (p < 0.0005), yet both required canes at similar ages: 58.8 years for men and 60.1 for women (p = 0.082). A younger onset age predicted a slower progression, but those older at onset were consistently older when reaching EDSS 6. A primary progressive course predicted a more rapid progression from both onset (p < 0.0005) and birth (hazard ratio = 2.7 [95% CI: 2.2 to 3.3]). No onset symptom consistently predicted progression.
CONCLUSION: Disability progression in multiple sclerosis (MS) accrued more slowly than found in earlier longitudinal studies. The authors also challenged two fundamental concepts in MS, demonstrating that neither male sex nor older onset age was associated with worse disease outcome.

Entities:  

Mesh:

Year:  2006        PMID: 16434648     DOI: 10.1212/01.wnl.0000194259.90286.fe

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  74 in total

Review 1.  Benign multiple sclerosis: does it exist?

Authors:  Jorge Correale; María C Ysrraelit; Marcela P Fiol
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

2.  Multiple sclerosis affects the frequency content in the vertical ground reaction forces during walking.

Authors:  Shane R Wurdeman; Jessie M Huisinga; Mary Filipi; Nicholas Stergiou
Journal:  Clin Biomech (Bristol, Avon)       Date:  2010-10-29       Impact factor: 2.063

3.  Uphill and Downhill Walking in Multiple Sclerosis: A Randomized Controlled Trial.

Authors:  Afshin Samaei; Amir Hoshang Bakhtiary; Abdolhamid Hajihasani; Elham Fatemi; Fatemeh Motaharinezhad
Journal:  Int J MS Care       Date:  2016 Jan-Feb

Review 4.  Multiple sclerosis in the elderly patient.

Authors:  Amer Awad; Olaf Stüve
Journal:  Drugs Aging       Date:  2010-04-01       Impact factor: 3.923

Review 5.  Effects of the Menstrual Cycle on Neurological Disorders.

Authors:  Hannah J Roeder; Enrique C Leira
Journal:  Curr Neurol Neurosci Rep       Date:  2021-05-10       Impact factor: 5.081

Review 6.  Clinical prognostic factors in multiple sclerosis: a natural history review.

Authors:  Alexandra Degenhardt; Sreeram V Ramagopalan; Antonio Scalfari; George C Ebers
Journal:  Nat Rev Neurol       Date:  2009-12       Impact factor: 42.937

7.  A reduced somatosensory gating response in individuals with multiple sclerosis is related to walking impairment.

Authors:  David J Arpin; James E Gehringer; Tony W Wilson; Max J Kurz
Journal:  J Neurophysiol       Date:  2017-07-19       Impact factor: 2.714

8.  Variations in functioning and disability in multiple sclerosis. A two-year prospective study.

Authors:  Charlotte Ytterberg; Sverker Johansson; Magnus Andersson; Lotta Widén Holmqvist; Lena von Koch
Journal:  J Neurol       Date:  2008-06-17       Impact factor: 4.849

9.  Marginal structural Cox models for estimating the association between β-interferon exposure and disease progression in a multiple sclerosis cohort.

Authors:  Mohammad Ehsanul Karim; Paul Gustafson; John Petkau; Yinshan Zhao; Afsaneh Shirani; Elaine Kingwell; Charity Evans; Mia van der Kop; Joel Oger; Helen Tremlett
Journal:  Am J Epidemiol       Date:  2014-06-17       Impact factor: 4.897

10.  Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis.

Authors:  C L Hirst; A Pace; T P Pickersgill; R Jones; B N McLean; J P Zajicek; N J Scolding; N P Robertson
Journal:  J Neurol       Date:  2008-02-20       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.